Sagimet Biosciences Inc. (SGMT) Stock Forecast
SGMT analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 12 analysts
- Price target
- $27.91 average of analyst targets
- Upside to target
- +248.0% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.25
- 52-week range
- $4.55 – $11.17
SGMT analyst ratings
12 analystsNumber of analysts at each rating.
SGMT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SGMT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.26 | −$0.34 | −$0.20 | −$0.40 | +35.0% | 11 |
| Current fiscal year (2026) | −$1.12 | −$1.31 | −$0.96 | −$1.58 | +29.1% | 11 |
| Next fiscal year (2027) | −$1.30 | −$1.85 | −$0.39 | −$1.12 | −16.1% | 11 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SGMT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 11 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 11 |
| Next fiscal year (2027) | $8.5M | $0 | $80.9M | 0.0% | 11 |
SGMT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SGMT revenue: reported and forecast
SGMT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.26 | −$0.26 | −$0.26 | −$0.26 | −$0.26 | −0.1% | 0 up · 0 down |
| Current fiscal year (2026) | −$1.22 | −$1.22 | −$1.20 | −$1.16 | −$1.12 | −8.3% | 4 up · 0 down |
| Next fiscal year (2027) | −$1.31 | −$1.31 | −$1.38 | −$1.39 | −$1.30 | −0.8% | 5 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SGMT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SGMT beat in 9 of 12.
What analysts expect from SGMT
12 analysts cover Sagimet Biosciences; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $27.91, 248.0% above the latest close of $8.02. Analysts expect earnings of −$1.12 per share for 2026, +29.1% from a year earlier. For 2027 the average estimate is −$1.30 per share on revenue of $8.5 million. Sagimet Biosciences beat the EPS estimate in 9 of the last 12 quarters.
Related: SGMT income statement, SGMT key metrics, SGMT chart. See the SGMT stock overview for the latest quote and news.
SGMT forecast FAQ
What is Sagimet Biosciences's price target?
The average analyst price target for Sagimet Biosciences is $27.91, 248.0% above the latest close of $8.02.
Is Sagimet Biosciences a buy, hold or sell?
Of 12 analysts covering Sagimet Biosciences, 9 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 1 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Sagimet Biosciences's EPS forecast?
Analysts forecast −$1.12 per share for 2026 (range −$1.31 to −$0.96); for 2027 the estimate is −$1.30.
When does Sagimet Biosciences report earnings?
Sagimet Biosciences is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens; the EPS estimate is $-0.25.
Does Sagimet Biosciences usually beat earnings estimates?
Sagimet Biosciences reported EPS at or above the analyst estimate in 9 of the last 12 quarters.